What is the only way to prevent anaphylaxis

1. Sampson HA, Muñoz-Furlong A, Campbell RL, et al.: Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391–7. 10.1016/j.jaci.2005.12.1303 [PubMed] [CrossRef] [Google Scholar]

2. Johansson SG, Bieber T, Dahl R, et al.: Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832–6. 10.1016/j.jaci.2003.12.591 [PubMed] [CrossRef] [Google Scholar]

3. Muraro A, Roberts G, Worm M, et al.: Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69(8):1026–45. 10.1111/all.12437 [PubMed] [CrossRef] [Google Scholar]

4. Lieberman P, Camargo CA, Bohlke K, et al.: Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol. 2006;97(5):596–602. 10.1016/S1081-1206(10)61086-1 [PubMed] [CrossRef] [Google Scholar]

5. Wood RA, Camargo CA, Lieberman P, et al.: Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(2):461–7. 10.1016/j.jaci.2013.08.016 [PubMed] [CrossRef] [Google Scholar]

6. Lieberman P, Nicklas RA, Oppenheimer J, et al.: The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010;126(3):477–80.e1–42. 10.1016/j.jaci.2010.06.022 [PubMed] [CrossRef] [Google Scholar]

7. Derby CJ, Gowland MH, Hourihane JO: Sesame allergy in Britain: a questionnaire survey of members of the Anaphylaxis Campaign. Pediatr Allergy Immunol. 2005;16(2):171–5. 10.1111/j.1399-3038.2005.00232.x [PubMed] [CrossRef] [Google Scholar]

8. Gangur V, Kelly C, Navuluri L: Sesame allergy: a growing food allergy of global proportions? Ann Allergy Asthma Immunol. 2005;95(1):4–11; quiz 11-3, 44. 10.1016/S1081-1206(10)61181-7 [PubMed] [CrossRef] [Google Scholar]

9. Stevenson DD: Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am. 2004;24(3):491–505, vii. 10.1016/j.iac.2004.03.001 [PubMed] [CrossRef] [Google Scholar]

10. Patel DD, Goldberg RM: Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park). 2006;20(11):1373–82; discussion 1382, 1392–4, 1397. [PubMed] [Google Scholar]

11. Cox L, Platts-Mills TA, Finegold I, et al.: American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373–7. 10.1016/j.jaci.2007.09.032 [PubMed] [CrossRef] [Google Scholar]

12. Golden DB: Insect sting allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol. 2005;115(3):439–47; quiz 448. 10.1016/j.jaci.2005.01.005 [PubMed] [CrossRef] [Google Scholar]

13. Golden DB, Marsh DG, Kagey-Sobotka A, et al.: Epidemiology of insect venom sensitivity. JAMA. 1989;262(2):240–4. 10.1001/jama.1989.03430020082033 [PubMed] [CrossRef] [Google Scholar]

14. Dohi M, Suko M, Sugiyama H, et al.: Food-dependent, exercise-induced anaphylaxis: a study on 11 Japanese cases. J Allergy Clin Immunol. 1991;87(1 Pt 1):34–40. 10.1016/0091-6749(91)90210-F [PubMed] [CrossRef] [Google Scholar]

15. Harada S, Horikawa T, Ashida M, et al.: Aspirin enhances the induction of type I allergic symptoms when combined with food and exercise in patients with food-dependent exercise-induced anaphylaxis. Br J Dermatol. 2001;145(2):336–9. 10.1046/j.1365-2133.2001.04329.x [PubMed] [CrossRef] [Google Scholar]

16. Kidd JM, Cohen SH, Sosman AJ, et al.: Food-dependent exercise-induced anaphylaxis. J Allergy Clin Immunol. 1983;71(4):407–11. 10.1016/0091-6749(83)90070-2 [PubMed] [CrossRef] [Google Scholar]

17. Lockey RF, Benedict LM, Turkeltaub PC, et al.: Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987;79(4):660–77. 10.1016/S0091-6749(87)80164-1 [PubMed] [CrossRef] [Google Scholar]

18. Reid MJ, Lockey RF, Turkeltaub PC, et al.: Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol. 1993;92(1 Pt 1):6–15. 10.1016/0091-6749(93)90030-J [PubMed] [CrossRef] [Google Scholar]

19. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, et al.: Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol. 2001;87(1 Suppl 1):47–55. 10.1016/S1081-1206(10)62195-3 [PubMed] [CrossRef] [Google Scholar]

20. Bernstein DI, Wanner M, Borish L, et al.: Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol. 2004;113(6):1129–36. 10.1016/j.jaci.2004.02.006 [PubMed] [CrossRef] [Google Scholar]

21. Schwartz LB, Yunginger JW, Miller J, et al.: Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest. 1989;83(5):1551–5. 10.1172/JCI114051 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Schwartz LB, Bradford TR, Rouse C, et al.: Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol. 1994;14(3):190–204. 10.1007/BF01533368 [PubMed] [CrossRef] [Google Scholar]

23. Schwartz LB: Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. 2006;26(3):451–63. 10.1016/j.iac.2006.05.010 [PubMed] [CrossRef] [Google Scholar]

24. Schwartz LB, Metcalfe DD, Miller JS, et al.: Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med. 1987;316(26):1622–6. 10.1056/NEJM198706253162603 [PubMed] [CrossRef] [Google Scholar]

25. Valent P, Akin C, Arock M, et al.: Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215–25. 10.1159/000328760 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Simons FE, Gu X, Simons KJ: Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol. 2001;108(5):871–3. 10.1067/mai.2001.119409 [PubMed] [CrossRef] [Google Scholar]

27. Toogood JH: Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol. 1988;81(1):1–5. 10.1016/0091-6749(88)90212-6 [PubMed] [CrossRef] [Google Scholar]

28. Vander Zanden JA, Valuck RJ, Bunch CL, et al.: Systemic adverse effects of ophthalmic beta-blockers. Ann Pharmacother. 2001;35(12):1633–7. 10.1345/aph.18464 [PubMed] [CrossRef] [Google Scholar]

29. Lang DM, Alpern MB, Visintainer PF, et al.: Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med. 1991;115(4):270–6. 10.7326/0003-4819-115-4-270 [PubMed] [CrossRef] [Google Scholar]

30. Pollack CV, Jr: Utility of glucagon in the emergency department. J Emerg Med. 1993;11(2):195–205. 10.1016/0736-4679(93)90519-D [PubMed] [CrossRef] [Google Scholar]

31. Sherman MS, Lazar EJ, Eichacker P: A bronchodilator action of glucagon. J Allergy Clin Immunol. 1988;81(5 Pt 1):908–11. [PubMed] [Google Scholar]

32. Fisher MM: Clinical observations on the pathophysiology and treatment of anaphylactic cardiovascular collapse. Anaesth Intensive Care. 1986;14(1):17–21. [PubMed] [Google Scholar]

33. Fisher M: Blood volume replacement in acute anaphylactic cardiovascular collapse related to anaesthesia. Br J Anaesth. 1977;49(10):1023–6. 10.1093/bja/49.10.1023 [PubMed] [CrossRef] [Google Scholar]

34. Pumphrey RS: Fatal posture in anaphylactic shock. J Allergy Clin Immunol. 2003;112(2):451–2. 10.1067/mai.2003.1614 [PubMed] [CrossRef] [Google Scholar]

35. Sheikh A, Ten Broek V, Brown SG, et al.: H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2007;62(8):830–7. 10.1111/j.1398-9995.2007.01435.x [PubMed] [CrossRef] [Google Scholar]

36. Choo KJL, Simons E, Sheikh A: Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2010;65(10):1205–11. 10.1111/j.1398-9995.2010.02424.x [PubMed] [CrossRef] [Google Scholar]

37. Lieberman P: Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol. 2005;95(3):217–26; quiz 26, 58. 10.1016/S1081-1206(10)61217-3 [PubMed] [CrossRef] [Google Scholar]

38. Alqurashi W, Stiell I, Chan K, et al.: Epidemiology and clinical predictors of biphasic reactions in children with anaphylaxis. Ann Allergy Asthma Immunol. 2015;115(3):217–223.e2. 10.1016/j.anai.2015.05.013 [PubMed] [CrossRef] [Google Scholar]

39. Grunau BE, Li J, Yi TW, et al.: Incidence of clinically important biphasic reactions in emergency department patients with allergic reactions or anaphylaxis. Ann Emerg Med. 2014;63(6):736–44.e2. 10.1016/j.annemergmed.2013.10.017 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

40. Tole JW, Lieberman P: Biphasic anaphylaxis: review of incidence, clinical predictors, and observation recommendations. Immunol Allergy Clin North Am. 2007;27(2):309–26, viii. 10.1016/j.iac.2007.03.011 [PubMed] [CrossRef] [Google Scholar]

41. Kemp SF: The post-anaphylaxis dilemma: how long is long enough to observe a patient after resolution of symptoms? Curr Allergy Asthma Rep. 2008;8(1):45–8. 10.1007/s11882-008-0009-7 [PubMed] [CrossRef] [Google Scholar]

42. Soar J, Perkins GD, Abbas G, et al.: European Resuscitation Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: Electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. Resuscitation. 2010;81(10):1400–33. 10.1016/j.resuscitation.2010.08.015 [PubMed] [CrossRef] [Google Scholar]

43. Scranton SE, Gonzalez EG, Waibel KH: Incidence and characteristics of biphasic reactions after allergen immunotherapy. J Allergy Clin Immunol. 2009;123(2):493–8. 10.1016/j.jaci.2008.10.026 [PubMed] [CrossRef] [Google Scholar]

44. Wang J, Sampson HA: Oral and sublingual immunotherapy for food allergy. Asian Pac J Allergy Immunol. 2013;31(3):198–209. [PubMed] [Google Scholar] F1000 Recommendation

45. Burks AW, Wood RA, Jones SM, et al.: Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol. 2015;135(5):1240–8.e1–3. 10.1016/j.jaci.2014.12.1917 [PMC free article] [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

46. Sampson HA: Peanut oral immunotherapy: is it ready for clinical practice? J Allergy Clin Immunol Pract. 2013;1(1):15–21. 10.1016/j.jaip.2012.10.009 [PubMed] [CrossRef] [Google Scholar]

48. Wood RA, Sampson HA: Oral immunotherapy for the treatment of peanut allergy: is it ready for prime time? J Allergy Clin Immunol Pract. 2014;2(1):97–8. 10.1016/j.jaip.2013.11.010 [PubMed] [CrossRef] [Google Scholar]

49. Fleischer DM, Burks AW, Vickery BP, et al.: Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131(1):119–27.e1–7. 10.1016/j.jaci.2012.11.011 [PMC free article] [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

51. Goldberg MR, Nachshon L, Appel MY, et al.: Efficacy of baked milk oral immunotherapy in baked milk-reactive allergic patients. J Allergy Clin Immunol. 2015;136(6): pii: S0091-6749(15)00794-0. 10.1016/j.jaci.2015.05.040 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

53. Raja AS, Lindsell CJ, Bernstein JA, et al.: The use of penicillin skin testing to assess the prevalence of penicillin allergy in an emergency department setting. Ann Emerg Med. 2009;54(1):72–7. 10.1016/j.annemergmed.2008.12.034 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

54. Brockow K, Garvey LH, Aberer W, et al.: Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702–12. 10.1111/all.12142 [PubMed] [CrossRef] [Google Scholar]

55. Romano A, Caubet JC: Antibiotic allergies in children and adults: from clinical symptoms to skin testing diagnosis. J Allergy Clin Immunol Pract. 2014;2(1):3–12. 10.1016/j.jaip.2013.11.006 [PubMed] [CrossRef] [Google Scholar]

56. Castells M: Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am. 2009;29(3):585–606. 10.1016/j.iac.2009.04.012 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

57. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; et al. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259–73. 10.1016/j.anai.2010.08.002 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

58. Moffitt JE, Golden DB, Reisman RE, et al.: Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol. 2004;114(4):869–86. 10.1016/j.jaci.2004.07.046 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

59. Committee on Insects: The discontinuation of Hymenoptera venom immunotherapy. J Allergy Clin Immunol. 1998;101(5):573–5. 10.1016/S0091-6749(98)70161-7 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

60. Golden DB, Kwiterovich KA, Kagey-Sobotka A, et al.: Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol. 1996;97(2):579–87. 10.1016/S0091-6749(96)70302-0 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

61. Lerch E, Müller UR: Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol. 1998;101(5):606–12. 10.1016/S0091-6749(98)70167-8 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

62. Metcalfe DD, Schwartz LB: Assessing anaphylactic risk? Consider mast cell clonality. J Allergy Clin Immunol. 2009;123(3):687–8. 10.1016/j.jaci.2009.02.003 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

63. Zanotti R, Lombardo C, Passalacqua G, et al.: Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol. 2015;136(1):135–9. 10.1016/j.jaci.2014.11.035 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

64. Maulitz RM, Pratt DS, Schocket AL: Exercise-induced anaphylactic reaction to shellfish. J Allergy Clin Immunol. 1979;63(6):433–4. 10.1016/0091-6749(79)90218-5 [PubMed] [CrossRef] [Google Scholar]

65. Sheffer AL, Austen KF: Exercise-induced anaphylaxis. J Allergy Clin Immunol. 1980;66(2):106–11. 10.1016/0091-6749(80)90056-1 [PubMed] [CrossRef] [Google Scholar]

66. Shadick NA, Liang MH, Partridge AJ, et al.: The natural history of exercise-induced anaphylaxis: survey results from a 10-year follow-up study. J Allergy Clin Immunol. 1999;104(1):123–7. 10.1016/S0091-6749(99)70123-5 [PubMed] [CrossRef] [Google Scholar]

67. Untersmayr E, Bakos N, Schöll I, et al.: Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J. 2005;19(6):656–8. 10.1096/fj.04-3170fje [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

68. Steinke JW, Platts-Mills TA, Commins SP: The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol. 2015;135(3):589–96; quiz 597. 10.1016/j.jaci.2014.12.1947 [PMC free article] [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

69. Commins SP, Satinover SM, Hosen J, et al.: Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 2009;123(2):426–33. 10.1016/j.jaci.2008.10.052 [PMC free article] [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

70. Bonadonna P, Perbellini O, Passalacqua G, et al.: Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123(3):680–6. 10.1016/j.jaci.2008.11.018 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

71. Akin C, Scott LM, Kocabas CN, et al.: Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood. 2007;110(7):2331–3. 10.1182/blood-2006-06-028100 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

72. Ravi A, Butterfield J, Weiler CR: Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α. J Allergy Clin Immunol Pract. 2014;2(6):775–8. 10.1016/j.jaip.2014.06.011 [PubMed] [CrossRef] [Google Scholar]

73. Wilkin JK, Wilkin O, Kapp R, et al.: Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther. 1982;31(4):478–82. 10.1038/clpt.1982.63 [PubMed] [CrossRef] [Google Scholar]

74. Ditto AM, Harris KE, Krasnick J, et al.: Idiopathic anaphylaxis: a series of 335 cases. Ann Allergy Asthma Immunol. 1996;77(4):285–91. 10.1016/S1081-1206(10)63322-4 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

75. Wong S, Yarnold PR, Yango C, et al.: Outcome of prophylactic therapy for idiopathic anaphylaxis. Ann Intern Med. 1991;114(2):133–6. 10.7326/0003-4819-114-2-133 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

76. Jones JD, Marney SR, Jr, Fahrenholz JM: Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol. 2008;101(5):550–1. 10.1016/S1081-1206(10)60296-7 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

77. Warrier P, Casale TB: Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol. 2009;102(3):257–8. 10.1016/S1081-1206(10)60091-9 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

78. Demirtürk M, Gelincik A, Colakoğlu B, et al.: Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol. 2012;39(6):552–4. 10.1111/j.1346-8138.2012.01520.x [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation

What is the most important way to prevent life threatening anaphylaxis?

What is the only effective way to treat anaphylaxis?

How is anaphylaxis treated and prevented?

How do you prevent future anaphylaxis?